Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome

Neurobiology of Aging

Volumn 38, Issue , 2016, Pages 151-163

  Pan, Xiaobei ^a   Nasaruddin, Muhammad Bin ^a   Elliott, Christopher T ^a   McGuinness, Bernadette ^b   Passmore, Anthony P ^b   Kehoe, Patrick G ^c   Hölscher, Christian ^d   McClean, Paula L ^e   Graham, Stewart F ^f   Green, Brian D ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d LANCASTER UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF ULSTER   (United Kingdom)

^f Beaumont Research Institute   (United States)

Author keywords

Alzheimer's disease; APP PS1; Blood; Brain; Metabolites; Metabolomics

Indexed keywords

ACYLCARNITINE; BRANCHED CHAIN AMINO ACID; ESSENTIAL AMINO ACID; PHOSPHOLIPID; SEROTONIN; CARNITINE; POLYAMINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; MALE; METABOLITE; METABOLOME; METABOLOMICS; MOUSE; MULTIVARIATE ANALYSIS; NONHUMAN; PATHOGENESIS; PHOSPHOLIPID METABOLISM; PLASMA; POLYAMINE METABOLISM; PRIORITY JOURNAL; TRANSGENIC MOUSE; AGING; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; BRAIN; DISEASE MODEL; METABOLISM;

AGING; ALZHEIMER DISEASE; AMINO ACIDS, BRANCHED-CHAIN; AMINO ACIDS, ESSENTIAL; ANIMALS; BIOGENIC POLYAMINES; BRAIN; CARNITINE; DISEASE MODELS, ANIMAL; MALE; METABOLOME; MICE, TRANSGENIC; PHOSPHOLIPIDS; SEROTONIN;

EID: 84962214982     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2015.11.014     Document Type: Article

References (60)

1. Barrier L., Fauconneau B., Noel A., Ingrand S. Ceramide and related sphingolipid levels are not altered in disease associated brain regions of APP and APP/PS1 mouse models of Alzheimer's disease: relationship with the lack of neurodegeneration?. Int. J. Alzheimers Dis. 2010, 2011:920958.
2. Beckonert O., Keun H.C., Ebbels T.M.D., Bundy J.G., Holmes E., Lindon J.C., Nicholson J.K. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat. Protoc. 2007, 2:2692-2703.
3. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
4. Borchelt D.R., Ratovitski T., vanLare J., Lee M.K., Gonzales V., Jenkins N.A., Copeland N.G., Price D.L., Sisodia S.S. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19:939-945.
5. Brauner-Osborne H., Egebjerg J., Nielsen E.O., Madsen U., Krogsgaard-Larsen P. Ligands for glutamate receptors: design and therapeutic prospects. J. Med. Chem. 2000, 43:2609-2645.
6. Butterfield D.A., Pocernich C.B. The glutamatergic system and Alzheimer's disease-therapeutic implications. CNS Drugs 2003, 17:641-652.
7. Cacabelos R., Takeda M., Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease. Int. J. Geriatr. Psychiatry 1999, 14:3-47.
8. Caraux G., Pinloche S. PermutMatrix: a graphical environment to arrange gene expression profiles in optimal linear order. Bioinformatics 2005, 21:1280-1281.
9. Chen S.Q., Cai Q., Shen Y.Y., Wang P.J., Teng G.J., Zhang W., Zang F.C. Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice. Behav. Brain Res. 2012, 235:1-6.
10. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., Troncoso J.C., Mattson M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2070-2075.
11. Dunn W.B., Lin W., Broadhurst D., Begley P., Brown M., Zelena E., Vaughan A.A., Halsall A., Harding N., Knowles J.D., Francis-McIntyre S., Tseng A., Ellis D.I., O'Hagan S., Aarons G., Benjamin B., Chew-Graham S., Moseley C., Potter P., Winder C.L., Potts C., Thornton P., McWhirter C., Zubair M., Pan M., Burns A., Cruickshank J.K., Jayson G.C., Purandare N., Wu F.C., Finn J.D., Haselden J.N., Nicholls A.W., Wilson I.D., Goodacre R., Kell D.B. Molecular phenotyping of a UK population: defining the human serum metabolome. Metabolomics 2015, 11:9-26.
12. Fabelo N., Martin V., Marin R., Santpere G., Aso E., Ferrer I., Diaz M. Evidence for premature lipid raft aging in APP/PS1 double transgenic mice, a model of familial Alzheimer disease. J. Neuropathol. Exp. Neurol. 2012, 71:868-881.
13. Farooqui A.A., Horrocks L.A., Farooqui T. Glycerophospholipids in brain: their metabolism, incorporation into membranes, functions, and involvement in neurological disorders. Chem. Phys. Lipids 2000, 106:1-29.
14. Farooqui A.A., Horrocks L.A., Farooqui T. Interactions between neural membrane glycerophospholipid and sphingolipid mediators: a recipe for neural cell survival or suicide. J. Neurosci. Res. 2007, 85:1834-1850.
15. Fiehn O. Metabolomics-the link between genotypes and phenotypes. Plant Mol. Biol. 2002, 48:155-171.
16. Gattaz W.F., Cairns N.J., Levy R., Forstl H., Braus D.F., Maras A. Decreased phospholipase A(2) activity in the brain and in platelets of patients with Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 1996, 246:129-131.
17. Gattaz W.F., Maras A., Cairns N.J., Levy R., Forstl H. Decreased phospholipase A(2) activity in Alzheimer brains. Biol. Psychiatry 1995, 37:13-17.
18. Gomes G.M., Dalmolin G.D., Baer J., Karpova A., Mello C.F., Kreutz M.R., Rubin M.A. Inhibition of the polyamine system counteracts beta-amyloid peptide-induced memory impairment in mice: Involvement of extrasynaptic NMDA receptors. PLoS One 2014, 9:e99184.
19. Gonzalez-Dominguez R., Garcia A., Garcia-Barrera T., Barbas C., Luis Gomez-Ariza J. Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry. Electrophoresis 2014, 35:3321-3330.
20. Gonzalez-Dominguez R., Garcia-Barrera T., Vitorica J., Gomez-Ariza J.L. Deciphering metabolic abnormalities associated with Alzheimer's disease in the APP/PS1 mouse model using integrated metabolomic approaches. Biochimie 2015, 110C:119-128.
21. Gonzalez-Dominguez R., Garcia-Barrera T., Vitorica J., Gomez-Ariza J.L. Metabolomics reveals significant impairments in the immune system of the APP/PS1 transgenic mice of Alzheimer's disease. Electrophoresis 2015, 36:577-587.
22. González-Domínguez R., García-Barrera T., Vitorica J., Gómez-Ariza J.L. Region-specific metabolic alterations in the brain of the APP/PS1 transgenic mice of Alzheimer's disease. Biochim. Biophys. Acta 2014, 1842:2395-2402.
23. Graham S.F., Chevallier O.P., Elliott C.T., Holscher C., Johnston J., McGuinness B., Kehoe P.G., Passmore A.P., Green B.D. Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease. PLoS One 2015, 10:e0119452.
24. Graham S.F., Chevallier O.P., Roberts D., Hoelscher C., Elliott C.T., Green B.D. Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease. Anal. Chem. 2013, 85:1803-1811.
25. Graham S.F., Holscher C., McClean P., Elliott C.T., Green B.D. H-1 NMR metabolomics investigation of an Alzheimer's disease (AD) mouse model pinpoints important biochemical disturbances in brain and plasma. Metabolomics 2013, 9:974-983.
26. Grimm M.O.W., Grimm H.S., Patzold A.J., Zinser E.G., Halonen R., Duering M., Tschape J.A., De Strooper B., Muller U., Shen J., Hartmann T. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 2005, 7:1118-1123.
27. Grimm M.O.W., Groesgen S., Riemenschneider M., Tanila H., Grimm H.S., Hartmann T. From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. J. Chromatogr. A 2011, 1218:7713-7722.
28. Guldbrandt M., Johansen T.N., Frydenvang K., Brauner-Osborne H., Stensbol T.B., Nielsen B., Karla R., Santi F., Krogsgaard-Larsen P., Madsen U. Glutamate receptor ligands: synthesis, stereochemistry, and enantiopharmacology of methylated 2-aminoadipic acid analogs. Chirality 2002, 14:351-363.
29. Hamilton A., Holscher C. The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease. Brain Res. 2012, 1449:83-93.
30. Inoue K., Tsutsui H., Akatsu H., Hashizume Y., Matsukawa N., Yamamoto T., Toyo'oka T. Metabolic profiling of Alzheimer's disease brains. Sci. Rep. 2013, 3:2364.
31. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., Borchelt D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004, 13:159-170.
32. Junker B.H., Klukas C., Schreiber F. VANTED: a system for advanced data analysis and visualization in the context of biological networks. BMC Bioinformatics 2006, 7:109.
33. Lalonde R., Kim H.D., Maxwell J.A., Fukuchi K. Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/Delta E9 mice with amyloid plaques. Neurosci. Lett. 2005, 390:87-92.
34. Larsson Forsell P.K., Kennedy B.P., Claesson H.E. The human calcium-independent phospholipase A2 gene multiple enzymes with distinct properties from a single gene. Eur. J. Biochem. 1999, 262:575-585.
35. Mancuso D.J., Jenkins C.M., Gross R.W. The genomic organization, complete mRNA sequence, cloning, and expression of a novel human intracellular membrane-associated calcium-independent phospholipase A(2). J. Biol. Chem. 2000, 275:9937-9945.
36. Marjanska M., Curran G.L., Wengenack T.M., Henry P.G., Bliss R.L., Poduslo J.F., Jack C.R., Ugurbil K., Garwood M. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11906-11910.
37. Mi W., van Wijk N., Cansev M., Sijben J.W., Kamphuis P.J. Nutritional approaches in the risk reduction and management of Alzheimer's disease. Nutrition 2013, 29:1080-1089.
38. Moskovitz J., Maiti P., Lopes D.H.J., Oien D.B., Attar A., Liu T., Mittal S., Hayes J., Bitan G. Induction of methionine sulfoxide reductases protects neurons from amyloid beta protein insults in vitro and in vivo. Biochemistry 2011, 50:10687-10697.
39. Nkuipou-Kenfack E., Duranton F., Gayrard N., Argiles A., Lundin U., Weinberger K.M., Dakna M., Delles C., Mullen W., Husi H., Klein J., Koeck T., Zuerbig P., Mischak H. Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease. PLoS One 2014, 9:e96955.
40. Prince M., Albanese E., Guerchet M., Prina M., Prince M., Albanese E., Guerchet M., Prina M. World Alzheimer Report 2014 2014, Alzheimer's Disease International, London.
41. Prokazova N.V., Zvezdina N.D., Korotaeva A.A. Effect of lysophosphatidylcholine on transmembrane signal transduction. Biochemistry (Mosc) 1998, 63:31-37.
42. Puglielli L., Ellis B.C., Saunders A.J., Kovacs D.M. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J. Biol. Chem. 2003, 278:19777-19783.
43. Qiao Q., Li T., Sun J., Liu X., Ren J., Fei J. Metabolomic analysis of normal (C57BL/6J, 129S1/SvImJ) mice by gas chromatography-mass spectrometry: detection of strain and gender differences. Talanta 2011, 85:718-724.
44. Roemisch-Margl W., Prehn C., Bogumil R., Roehring C., Suhre K., Adamski J. Procedure for tissue sample preparation and metabolite extraction for high-throughput targeted metabolomics. Metabolomics 2012, 8:133-142.
45. Schaeffer E.L., Forlenza O.V., Gattaz W.F. Phospholipase A(2) activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology (Berl) 2009, 202:37-51.
46. Schaeffer E.L., Gattaz W.F. Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A(2) enzyme. Psychopharmacology (Berl) 2008, 198:1-27.
47. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
48. Selkoe D.J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol. 2004, 6:1054-1061.
49. Selkoe D.J., Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 2003, 43:545-584.
50. Skovronsky D.M., Lee V.M.Y., Trojanowskiz J.Q. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu. Rev. Pathol. 2006, 1:151-170.
51. Stephenson D.T., Lemere C.A., Selkoe D.J., Clemens J.A. Cytosolic phospholipase A(2) (cPLA(2)) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol. Dis. 1996, 3:51-63.
52. Trushina E., Dutta T., Persson X.M.T., Mielke M.M., Petersen R.C. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS One 2013, 8:e63644.
53. Trushina E., Nemutlu E., Zhang S., Christensen T., Camp J., Mesa J., Siddiqui A., Tamura Y., Sesaki H., Wengenack T.M., Dzeja P.P., Poduslo J.F. Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer's disease. PLoS One 2012, 7:e32737.
54. Urban M., Enot D.P., Dallmann G., Korner L., Forcher V., Enoh P., Koal T., Keller M., Deigner H.P. Complexity and pitfalls of mass spectrometry-based targeted metabolomics in brain research. Anal. Biochem. 2010, 406:124-131.
55. Volianskis A., Kostner R., Molgaard M., Hass S., Jensen M.S. Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1 Delta E9-deleted transgenic mice model of beta-amyloidosis. Neurobiol. Aging 2010, 31:1173-1187.
56. Xia J., Mandal R., Sinelnikov I.V., Broadhurst D., Wishart D.S. MetaboAnalyst 2.0-A comprehensive server for metabolomic data analysis. Nucleic Acids Res. 2012, 40:W127-W133.
57. Xiong H., Callaghan D., Wodzinska J., Xu J., Premyslova M., Liu Q.Y., Connelly J., Zhang W. Biochemical and behavioral characterization of the double transgenic mouse model (APPswe/PS1dE9) of Alzheimer's disease. Neurosci. Bull. 2011, 27:221-232.
58. Yao J.K., Wengenack T.M., Curran G.L., Poduslo J.F. Reduced membrane lipids in the cortex of Alzheimer's disease transgenic mice. Neurochem. Res. 2009, 34:102-108.
59. Yatin S.M., Yatin M., Aulick T., Ain K.B., Butterfield D.A. Alzheimer's amyloid beta-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and ornithine decarboxylase activity: protective effect of vitamin E. Neurosci. Lett. 1999, 263:17-20.
60. Yatin S.M., Yatin M., Varadarajan S., Ain K.B., Butterfield D.A. Role of spermine in amyloid beta-peptide-associated free radical-induced neurotoxicity. J. Neurosci. Res. 2001, 63:395-401.